2.19%
2.94%
2.94%
2.56%
-6.67%
-23.71%
30.84%

Company Description

Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally.It operates through Therapy, Plasma & Services, and Other segments.The company offers its products in hematology, clinical immunology, and intensive care medicine areas.


Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis.The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation.In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections.


The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986.The company was founded in 1946 and is headquartered in Dreieich, Germany.As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.

Market Data

Last Price 28
Change Percentage 2.19%
Open 27.5
Previous Close 27.4
Market Cap ( Millions) 1391
Volume 28073
Year High 30.4
Year Low 22.8
M A 50 27.0
M A 200 27.11

Financial Ratios

FCF Yield 4.13%
Dividend Yield 0.14%
ROE 13.11%
Debt / Equity 0.00%
Net Debt / EBIDTA -25.08%
Price To Book 1.97
Price Earnings Ratio 15.21
Price To FCF 24.23
Price To sales 1.97
EV / EBITDA 13.87

Business Breakdown

Expected Mid-Term Growth

Segment nΒ°1 -> European Union

Expected Growth : 7.43 %

What the company do ?

The European Union is a political and economic union of 27 member states, promoting peace, stability, and economic cooperation in Europe, from Biotest AG's perspective.

Why we expect these perspectives ?

Biotest Aktiengesellschaft's 7.43% growth in the European Union is driven by increasing demand for plasma-based therapies, expansion into new markets, and strategic partnerships. The EU's growing elderly population and rising prevalence of chronic diseases also contribute to the growth. Additionally, the company's investments in research and development, as well as its focus on rare diseases, have led to new product launches and increased sales.

Segment nΒ°2 -> Rest of the World

Expected Growth : 8.5 %

What the company do ?

The Rest of the World segment from Biotest Aktiengesellschaft refers to the sales and operations of the company outside of Europe and the United States.

Why we expect these perspectives ?

The 8.5% growth in the Rest of the World segment of Biotest Aktiengesellschaft is driven by increasing demand for plasma-based therapies, expansion into emerging markets, and strategic partnerships. Additionally, growing healthcare expenditure and investments in healthcare infrastructure in regions such as Asia and Latin America are contributing to this growth.

Segment nΒ°3 -> Stateless

Expected Growth : 8.5 %

What the company do ?

Stateless from Biotest Aktiengesellschaft refers to a bioreactor design that eliminates the need for cleaning and sterilization between batches, reducing production downtime and increasing efficiency.

Why we expect these perspectives ?

Stateless from Biotest Aktiengesellschaft's 8.5% growth is driven by increasing demand for plasma-based therapies, expansion into new markets, and strategic partnerships. Additionally, investments in R&D and manufacturing capacity enhancements have improved operational efficiency, contributing to the company's growth momentum.

Biotest Aktiengesellschaft Products

Product Range What is it ?
Biotest Plasma Biotest Plasma is a pharmaceutical product used to treat various diseases and disorders, including immunodeficiency disorders, bleeding disorders, and infectious diseases.
Biotest Albumin Biotest Albumin is a pharmaceutical product used to treat hypovolemia, shock, and burns, as well as to prevent and treat bleeding complications.
Biotest Immunoglobulins Biotest Immunoglobulins are pharmaceutical products used to treat various immune system disorders, including primary immunodeficiency diseases and autoimmune diseases.
Biotest Coagulation Factors Biotest Coagulation Factors are pharmaceutical products used to treat bleeding disorders, including hemophilia A and B.
Biotest Hyperimmune Globulins Biotest Hyperimmune Globulins are pharmaceutical products used to treat and prevent infectious diseases, including rabies, tetanus, and hepatitis.

Biotest Aktiengesellschaft's Porter Forces

The threat of substitutes for Biotest Aktiengesellschaft is medium due to the presence of alternative products and services in the biotechnology industry.

The bargaining power of customers for Biotest Aktiengesellschaft is low due to the specialized nature of its products and services, which limits the ability of customers to negotiate prices.

The bargaining power of suppliers for Biotest Aktiengesellschaft is medium due to the presence of multiple suppliers in the market, which limits their bargaining power.

The threat of new entrants for Biotest Aktiengesellschaft is high due to the growing demand for biotechnology products and services, which attracts new entrants to the market.

The intensity of rivalry for Biotest Aktiengesellschaft is high due to the presence of established competitors in the biotechnology industry, which leads to intense competition.

Capital Structure

Value
Debt Weight 56.09%
Debt Cost 4.85%
Equity Weight 43.91%
Equity Cost 5.14%
WACC 4.98%
Leverage 127.76%

Historical Valuation

Price/Earnings Ratio

Margin Valuation

Peers Valuation

Competitors

Company Rational
MEDCL.PA MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends …
GLPG.AS Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that …
KURN.SW Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. …
NANO.PA Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles …
BAVA.CO Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under …

Peers Metrics

DCF BETA

Parameters

Short Term Growth
Short term Time
Long-Term Growth
WACC
Target Price
28.0$
Current Price
28$
Potential
-0.00%

Expected Cash-Flows

Scoring Insights

Peers Group Analysis

πŸ₯‡

MedinCell Logo
MedinCell
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

πŸ₯ˆ

Kuros Biosciences Logo
Kuros Biosciences
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

πŸ₯‰

Galapagos Logo
Galapagos
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

4

Bavarian Nordic Logo
Bavarian Nordic
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

5

Biotest Logo
Biotest
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

6

Nanobiotix Logo
Nanobiotix
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->